Clinical Trial Update: ANC-501 in the Treatment of Adults With Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ANC-501 for adults with major depressive disorder has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• ANC-501

Snippet

Sponsor: Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2024-12-31